European journal of rheumatology最新文献

筛选
英文 中文
Ultrasound in the Evaluation of Dactylitis and Enthesitis in Psoriatic Arthritis. 超声波评估银屑病关节炎的趾关节炎和足内翻。
IF 1.3
European journal of rheumatology Pub Date : 2024-01-18 DOI: 10.5152/eurjrheum.2024.21096
Ana Urruticoechea-Arana, Mireia Moreno, Manuel Pujol, Teresa Clavaguera
{"title":"Ultrasound in the Evaluation of Dactylitis and Enthesitis in Psoriatic Arthritis.","authors":"Ana Urruticoechea-Arana, Mireia Moreno, Manuel Pujol, Teresa Clavaguera","doi":"10.5152/eurjrheum.2024.21096","DOIUrl":"10.5152/eurjrheum.2024.21096","url":null,"abstract":"<p><p>Dactylitis is a clinical concept that corresponds to the swelling of the whole finger or toe giving a sausage appearance. Although it can be observed in different diseases, it is a distinctive clinical feature of psoriatic arthritis and is associated with a poor prognosis. Ultrasound has made it possible to improve our understanding of the pathogenesis of psoriatic arthritis dactylitis, identifying associated structural alterations, namely, flexor tenosynovitis, subcutaneous tissue edema, pulley inflammation with thickening and intra-pulley Doppler signals, extensor paratenonitis, synovitis, pericapsular bone formation, and flexor enthesitis. Given its complexity, a consensus has yet to be reached on an ultrasound-based definition of dactylitis. In addition, enthesitis is one of the characteristic features of spondyloartritis. Enthesitis, like dactylitis, is among the clinical manifestations in the Assessment of SpondyloArthritis international Society classification criteria for both axial and peripheral spondyloartritis and is a key feature for classifying psoriatic arthritis with the Classification criteria for Psoriatic Arthritis criteria. Ultrasonography is a very useful tool for exploring the enthesis. We have a good sonographic definition, although ultrasound findings do not always allow us to differentiate between mechanical or inflammatory lesions. Elementary lesions that characterize enthesopathy are hypoechogenicity at the enthesis, thickened enthesis, calcification/enthesophyte at enthesis, erosion at enthesis, and Doppler signal at enthesis. Different composite indices have been proposed in order to classify spond yloarthropathies. This article reviews the evaluation of dactylitis and enthesitis from the sonographic perspective.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"11 3","pages":"S298-S304"},"PeriodicalIF":1.3,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy. 免疫检查点抑制剂诱发的炎症性关节炎:疗法概述和优化联合疗法的个性化方法。
IF 1.3
European journal of rheumatology Pub Date : 2024-01-11 DOI: 10.5152/eurjrheum.2024.23091
Noa Rose, Victoria Furer, Ari Polachek, Ori Elkayam, Smadar Gertel
{"title":"Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy.","authors":"Noa Rose, Victoria Furer, Ari Polachek, Ori Elkayam, Smadar Gertel","doi":"10.5152/eurjrheum.2024.23091","DOIUrl":"10.5152/eurjrheum.2024.23091","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4, anti-programmed cell death 1, and anti-programmed cell death ligand 1 (PD-L1) antibodies, are currently widely used in oncology clinical practice, achieving considerable success in improving disease outcomes. New checkpoint targets are being discovered and investigated through basic science research and clinical trials. ICI remove negative regulatory immune signals on T cells, leading to immune activation and induction of antitumor immunity. Patients who receive ICI, however, are at risk for developing immune-related adverse events (irAEs), which are attributed to increased T cell activity against antigens in both tumors and in healthy tissues, to increased inflammatory cytokine levels, to increased levels of preexisting autoantibodies, and to enhanced complement-mediated inflammation. Arthritis is one of the most common irAEs. ICI-induced rheumatic irAEs are categorized by levels of severity which guide the choice of treatment options. Management of ICI-induced rheumatic irAEs includes the use of glucocorticoids, disease-modifying antirheumatic drugs (mainly methotrexate), and biological agents (e.g., tumor necrosis factor, interleukin-6 receptor, and CD20 inhibitors). This review aims to summarize the current ICI subtypes, their role in rheumatic irAEs development, and therapies currently used in clinical practice to manage irAEs. In addition, we propose to use an ex vivo personalized diagnostic assay for the selection of the most effective ICI with antirheumatic drugs combinations that will inhibit the advancement of ICI-induced adverse events.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Senescence in Osteoarthritis: Overview of Mechanisms and Therapeutics. 骨关节炎的衰老:机制和治疗综述。
IF 1.9
European journal of rheumatology Pub Date : 2023-11-28 DOI: 10.5152/eurjrheum.2023.22077
Natalya Surmachevska, Jose Rubio
{"title":"Senescence in Osteoarthritis: Overview of Mechanisms and Therapeutics.","authors":"Natalya Surmachevska, Jose Rubio","doi":"10.5152/eurjrheum.2023.22077","DOIUrl":"10.5152/eurjrheum.2023.22077","url":null,"abstract":"<p><p>Osteoarthritis is a morbid and costly condition affecting an increasingly larger segment of the population with a lack of effective treatment options. The pathophysiology of osteoarthritis is poorly understood; cell senescence is deemed to be contributory. Senescence of joint tissues particularly chondrocytes, synoviocytes (fibroblasts), and adipocytes is implicated in the pathogenesis through the production of senescence-associated proteins. Senescence-associated proteins are cytokines, matrix degradation enzymes, and chemokines that contribute to an inflammatory milieu which leads to the propagation of senescence. Senescence-modifying therapies include senolytics which eliminate senescent cells and senomorphics which inhibit the senescence-associated protein production of senescent cells. Treatments being investigated include novel agents as well as agents previously used in other conditions in rheumatology and other fields.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11184960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138444354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Treatments for Osteoarthritis. 骨关节炎的外科治疗。
IF 1.9
European journal of rheumatology Pub Date : 2023-11-28 DOI: 10.5152/eurjrheum.2023.21193
Ilana Usiskin
{"title":"Surgical Treatments for Osteoarthritis.","authors":"Ilana Usiskin","doi":"10.5152/eurjrheum.2023.21193","DOIUrl":"10.5152/eurjrheum.2023.21193","url":null,"abstract":"<p><p>Osteoarthritis is a prevalent and disabling condition most commonly affecting the knees, hips, and hands. Since there are currently no disease-modifying therapies available, patients with persistent pain and functional impairment despite pharmacologic and other non-operative therapies should be considered for surgical management. For both knee and hip Osteoarthritis, the most common surgical approach is total joint arthroplasty, an elective surgical procedure that generally has favorable outcomes with most patients reporting significant improvements in pain, function, and quality of life. Total joint arthroplasty has relatively low complication rates, with most patients able to be discharged home following a short hospital stay. The optimal timing for undergoing total joint arthroplasty and patient appropriateness for surgery are important considerations, and the current guidelines leave timing and patient selection at the discretion of physicians. Surgical approaches for hand osteoarthritis are less common and more varied, and include both arthrodesis and arthroplasty.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11184963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138444383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resveratrol in Rheumatological Diseases: A Systematic Review. 白藜芦醇在风湿病中的应用:系统综述。
IF 1.9
European journal of rheumatology Pub Date : 2023-10-01 DOI: 10.5152/eurjrheum.2023.23064
Jozélio Freire de Carvalho, Aaron Lerner
{"title":"Resveratrol in Rheumatological Diseases: A Systematic Review.","authors":"Jozélio Freire de Carvalho, Aaron Lerner","doi":"10.5152/eurjrheum.2023.23064","DOIUrl":"10.5152/eurjrheum.2023.23064","url":null,"abstract":"<p><p>Resveratrol is an antioxidant with anti-inflammatory and cell-protective properties. The aim of our article is to review the use of resveratrol in rheumatic diseases. PubMed/Medline, Embase, and Scielo were screened for articles on resveratrol and rheumatic diseases in the period between of January 1966 and March 2023. Five articles were depicted, including 481 patients. The included diseases were osteoarthritis (n=3), rheumatoid arthritis (n=1), and Takayasu arteritis (n=1). The age varied from 32 to 58.2 years, and the female gender ranged from 62% to 74% in the studies. Disease duration ranged from 3.5 ± 3.2 to 9.4 ± 5.8 years. The resveratrol dosage went from 250 mg to 1000 mg/day. All those articles demonstrated improvements in the diverse rheumatic diseases, including pain intensity, function, disease activity (DAS 28), swelling joints, and reduced inflammation markers (erythrocyte sedimentation rate, C-reactive protein, interleukinIL-1, IL-6, and tumor necrosis factor). No side effects were detected in all studies. In conclusion, resveratrol seems to be a safe therapy for various rheumatic diseases, although the evidence is very limited. The improved subjective and objective complaints and laboratory parameters are promising. However, there is a need to reconfirm, reproduce, and investigate the topic in more extensive, well-controlled, double-blind, cross-over studies.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":"163-168"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuropsychiatric Manifestations in Systemic Lupus Erythematosus Patients at a Tertiary Hospital in Peru. 秘鲁一家三级医院系统性红斑狼疮患者的神经精神表现。
IF 1.9
European journal of rheumatology Pub Date : 2023-10-01 DOI: 10.5152/eurjrheum.2023.22095
Jose Camones-Huerta, Christian Arias-Osorio, Diana Rodriguez-Hurtado, Jose Aguilar-Olano
{"title":"Neuropsychiatric Manifestations in Systemic Lupus Erythematosus Patients at a Tertiary Hospital in Peru.","authors":"Jose Camones-Huerta, Christian Arias-Osorio, Diana Rodriguez-Hurtado, Jose Aguilar-Olano","doi":"10.5152/eurjrheum.2023.22095","DOIUrl":"10.5152/eurjrheum.2023.22095","url":null,"abstract":"<p><strong>Background: </strong>Systemic lupus erythematosus is a prevalent autoimmune disease that affects multiples systems, exerting its most incapacitating and life-threatening impact through neuropsychiatric involvement. According to the American College of Rheumatology (ACR), 19 neuropsychiatric syndromes types of SLE are classified into categories encompassing the central and peripheral nervous systems. This study aimed to investigate the frequency of neuropsychiatric manifestations in systemic lupus erythematosus patients admitted to Hospital Cayetano Heredia in Lima, Peru, between 2008 and 2019.</p><p><strong>Methods: </strong>A retrospective observational study was conducted, entailing the review of 240 medical records of patients diagnosed with systemic lupus erythematosus during the specified period, based on the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria. Among these records, 55 patients presented neuropsychiatric systemic lupus erythematosus (NPSLE). Data were collected using standardized form and entered into Microsoft Excel 2019 database. Statistical analysis was performed using Stata v16.</p><p><strong>Results: </strong>The frequency of neuropsychiatric compromise in systemic lupus erythematosus patients was found to be 22.91%. Among the 55 systemic lupus erythematosus patients, 40 demonstrated involvement of the central nervous system (72.72%), 2 exhibited involvement of the peripheral nervous system (3.63%), and 13 displayed involvement in both the central nervous system and peripheral nervous system (23.63%). The most prevalent psychiatric disorder observed was a major depressive disorder, with a prevalence rate of 30.9%.</p><p><strong>Conclusion: </strong>The study revealed a frequency of 22.91% for neuropsychiatric involvement in systemic lupus erythematosuspatients at Cayetano Heredia Hospital between 2008 and 2019, with central nervous system manifestations prevailing. Furthermore, the findings suggest that NPSLE commonly manifested after the diagnosis of systemic lupus erythematosus.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":"143-147"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Tangled Autoimmune Trio: Multiple Sclerosis, Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antineutrophil Cytoplasmic Antibody Vasculitis. 复杂的自身免疫三联征:多发性硬化、系统性红斑狼疮和抗中性粒细胞细胞质抗体血管炎。
IF 1.9
European journal of rheumatology Pub Date : 2023-10-01 DOI: 10.5152/eurjrheum.2023.23021
Rajaie Namas, Sarah Al Qassimi, Muriel Ghosn, Esat Memisoglu, Ahmad Alduaij, Leal Herlitz, Victoria A Mifsud
{"title":"A Tangled Autoimmune Trio: Multiple Sclerosis, Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antineutrophil Cytoplasmic Antibody Vasculitis.","authors":"Rajaie Namas, Sarah Al Qassimi, Muriel Ghosn, Esat Memisoglu, Ahmad Alduaij, Leal Herlitz, Victoria A Mifsud","doi":"10.5152/eurjrheum.2023.23021","DOIUrl":"10.5152/eurjrheum.2023.23021","url":null,"abstract":"<p><p>The coexistence of multiple autoimmune diseases in the same individual is unusual and has received little attention in the literature. We present a young female patient with multiple sclerosis, systemic lupus erythematosus, and biopsy-proven renal proteinase 3 antineutrophil cytoplasmic antibodyassociated vasculitis who responded well to intravenous rituximab clinically and serologically.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":"176-178"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronavirus Disease 2019 in Rheumatic Patients with Inflammatory Disorders: A Descriptive Study from a High Infection Incidence Region of Northern Spain. 2019年类风湿性关节炎患者的冠状病毒疾病:西班牙北部感染高发区的一项描述性研究。
IF 1.9
European journal of rheumatology Pub Date : 2023-10-01 DOI: 10.5152/eurjrheum.2023.21152
Orlando Pompei Fernández, Paula García Escudero, Marta González Fernández, Claudia Stoye, César Antonio Egües, Jose Francisco García Llorente, Itziar Calvo Zorrilla, Oihane Ibargüengoitia Barrena, Ana Ruibal-Escribano, Juan Ramón De Dios, Joaquín María Belzunegui Otano, Belén Álvarez Rodríguez, Susana Gil Barato, Elena Garmendia Sánchez, Margarida Vasques Rocha, Edurne Guerrero, Jaime Calvo-Alén
{"title":"Coronavirus Disease 2019 in Rheumatic Patients with Inflammatory Disorders: A Descriptive Study from a High Infection Incidence Region of Northern Spain.","authors":"Orlando Pompei Fernández, Paula García Escudero, Marta González Fernández, Claudia Stoye, César Antonio Egües, Jose Francisco García Llorente, Itziar Calvo Zorrilla, Oihane Ibargüengoitia Barrena, Ana Ruibal-Escribano, Juan Ramón De Dios, Joaquín María Belzunegui Otano, Belén Álvarez Rodríguez, Susana Gil Barato, Elena Garmendia Sánchez, Margarida Vasques Rocha, Edurne Guerrero, Jaime Calvo-Alén","doi":"10.5152/eurjrheum.2023.21152","DOIUrl":"10.5152/eurjrheum.2023.21152","url":null,"abstract":"<p><strong>Background: </strong>Since the first confirmed case of severe acute respiratory syndrome coronavirus 2 in Spain in January 2020, the susceptibility of patients with rheumatic disease has remained unclear. In this report, we will describe the main features of coronavirus disease 2019 (COVID-19) that occurred in rheumatic patients with inflammatory disorders and try to identify features associated with severe disease.</p><p><strong>Methods: </strong>We included all rheumatic patients with immune-mediated diseases followed at 6 centers belonging to the public healthcare system in the Basque Country (Spain) and diagnosed with COVID-19 from March 1, 2020, to May 31, 2020.</p><p><strong>Results: </strong>In total, 131 patients were included in this study. The most frequent rheumatic disease was rheumatoid arthritis (46.6%), and the main comorbidities were arterial hypertension (45%). Fortyseven percent were taking glucocorticoids (GC) (62 patients), 61.8% were under treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARD), and 25 patients (19.1%) were receiving targeted therapies (TT). Thirty-eight percent of patients required hospital admission, 2.3% required transfer to intensive care uni, and the rate of mortality was 9.2%. Associated factors in univariate analysis for a bad outcome were older age, use of GC, obesity, previous cardiovascular disease, and lymphopenia. Use of GC and lymphopenia remained within the multivariate model.</p><p><strong>Conclusion: </strong>The frequency of COVID-19 seems to be similar in rheumatic patients as in the general population. Advanced age, obesity, heart disease, glucocorticoids, and low levels of lymphocytes were more common among the patients with a bad outcome. Neither exposure to csDMARD nor TT was associated with severe cases.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 4","pages":"136-142"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54228383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infections in Patients with Systemic Lupus Erythematosus: The Contribution of Primary Immune Defects Versus Treatment-Induced Immunosuppression. 系统性红斑狼疮患者的感染:原发性免疫缺陷与治疗诱导的免疫抑制的关系。
IF 1.3
European journal of rheumatology Pub Date : 2023-10-01 DOI: 10.5152/eurjrheum.2023.23068
Ana Laura Fischer Kunzler, George C Tsokos
{"title":"Infections in Patients with Systemic Lupus Erythematosus: The Contribution of Primary Immune Defects Versus Treatment-Induced Immunosuppression.","authors":"Ana Laura Fischer Kunzler, George C Tsokos","doi":"10.5152/eurjrheum.2023.23068","DOIUrl":"10.5152/eurjrheum.2023.23068","url":null,"abstract":"<p><p>Patients with systemic lupus erythematosus experience high rates of infections. The use of immunosuppressive drugs to treat the disease, along with the fact that both the innate and adaptive branches of the immune system are compromised, account for the development of infections. In this communication, we briefly discuss the aberrant function of the immune system in patients with systemic lupus erythematosus and review the occurrence of infections that have been reported in clinical trials conducted to develop new therapeutics. Understanding the immune dysfunction in patients with systemic lupus erythematosus and the appearance of infections while trying to control the disease using immunosuppressive or immunomodulatory drugs should help limit infections and mitigate the associated morbidity and mortality.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":"148-158"},"PeriodicalIF":1.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thrombocytopenia in Patients with Systemic Lupus Erythematosus. 系统性红斑狼疮患者的血小板减少。
IF 1.9
European journal of rheumatology Pub Date : 2023-10-01 DOI: 10.5152/eurjrheum.2023.23069
Omer Nuri Pamuk
{"title":"Thrombocytopenia in Patients with Systemic Lupus Erythematosus.","authors":"Omer Nuri Pamuk","doi":"10.5152/eurjrheum.2023.23069","DOIUrl":"10.5152/eurjrheum.2023.23069","url":null,"abstract":"<p><p>Thrombocytopenia can be one of the first manifestations of systemic lupus erythematosus and occurs in up to 40% of patients. Additionally, approximately 2% of patients with primary immune thrombocytopenia may develop systemic lupus erythematosus. Systemic lupus erythematosus is a highly heterogeneous disease, and in some patients, it may present mainly with hematological findings. Thrombocytopenia associated with systemic lupus erythematosus is also diverse, ranging from asymptomatic to severe, acute, or chronic cases. Several studies suggest that the coexistence of immune thrombocytopenia and systemic lupus erythematosus may be linked to a shared genetic background among various autoimmune diseases. Studies have reported correlations between thrombocytopenia and increased disease activity as well as kidney and central nervous system involvement in systemic lupus erythematosus. Severe thrombocytopenia is considered a poor prognostic factor in systemic lupus erythematosus. Despite this knowledge, the exact cause of reduced platelet count in systemic lupus erythematosus remains relatively unknown. Mainly, an excess of platelet destruction and/or reduced production from megakaryocytes are considered the primary factors contributing to systemic lupus erythematosus-associated thrombocytopenia. Given the prognostic significance of thrombocytopenia, there is a possibility of a pathogenic mechanistic role of thrombocytopenia and platelets in systemic lupus erythematosus. In systemic lupus erythematosus, platelets are activated and play a role in promoting autoimmune and inflammatory responses by interacting with both the innate and adaptive immunity. There is no randomized clinical trial in the treatment of systemic lupus erythematosus-related thrombocytopenia. Treatment approach of thrombocytopenia in lupus is almost similar to the treatment of immune thrombocytopenia. Considering the role of platelets in both inflammation and tissue injury, platelet activation and platelet-immune cell interaction might be important therapeutic strategies in the treatment of systemic lupus erythematosus.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 4","pages":"159-162"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54228384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信